Von Willebrand disease

Genetics in Medicine

Volumn 13, Issue 5, 2011, Pages 365-376

  James, Paula D ^a   Goodeve, Anne C ^b,c  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c SHEFFIELD CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

genetic analysis; mutation; von Willebrand disease; von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; FIBRINOLYTIC AGENT; POLYMER; RISTOCETIN; VON WILLEBRAND FACTOR;

BLEEDING; BLOOD GROUP ABO SYSTEM; CELL INTERACTION; CHILDBIRTH; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; EPISTAXIS; GENETIC COUNSELING; GENETIC SCREENING; HETEROZYGOTE; HUMAN; MENORRHAGIA; MOLECULAR GENETICS; MOUTH CAVITY; QUANTITATIVE ANALYSIS; REVIEW; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; TOOTH EXTRACTION; VON WILLEBRAND DISEASE;

GENETIC ASSOCIATION STUDIES; GENETIC COUNSELING; GENETIC TESTING; HUMANS; VON WILLEBRAND DISEASES;

EID: 79955892713     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3182035931     Document Type: Review

References (110)

1. Von Willebrand EA. Hereditar pseudohemofili. Finska Lakarsallskapets Handl 1926;67:7-112.
2. Lynch DC, Zimmerman TS, Collins CJ, et al. Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method. Cell 1985;41:49-56. (Pubitemid 15068424)
3. Sadler JE, Shelton-Inloes BB, Sorace JM, et al. Cloning and characteriza-tion of two cDNAs coding for human von Willebrand factor. Proc Natl Acad Sci USA 1985;82:6394-6398. (Pubitemid 16230519)
4. Ginsburg D, Handin RI, Bonthron DT, et al. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 1985;228:1401-1406. (Pubitemid 15041316)
5. Verweij CL, Diergaarde PJ, Hart M, Pannekoek H. Full-length von Wil-lebrand factor (vWF) cDNA encodes a highly repetitive protein consider-ably larger than the mature vWF subunit. EMBO J 1986;5:1839-1847.
6. Bowman M, Hopman WM, Rapson D, et al. A prospective evaluation of the prevalence of symptomatic von Willebrand disease (VWD) in a pedi-atric primary care population. Pediatr Blood Cancer 2010;55:171-173.
7. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987;69:454-459. (Pubitemid 17022013)
8. Werner EJ, Broxson EH, Tucker EL, et al. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993;123:893-898. (Pubitemid 23353251)
9. Bloom AL. von Willebrand factor: clinical features of inherited and ac-quired disorders. Mayo Clin Proc 1991; 66: 743-751.
10. Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. J Thromb Haemost 2006;4:2103-2114. (Pubitemid 44403432)
11. Rodeghiero F. Management of menorrhagia in women with inherited bleeding disorders: general principles and use of desmopressin. Haemo-philia 2008;14(suppl 1):21-30.
12. James AH, Jamison MG. Bleeding events and other complications during pregnancy and childbirth in women with von Willebrand disease. J Thromb Haemost 2007;5:1165-1169. (Pubitemid 46902117)
13. Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4:766-773.
14. Bowman M, Mundell G, Grabell J, et al. Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease. J Thromb Haemost 2008;6:2062-2066.
15. Bowman M, Riddel J, Rand ML, et al. Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. J Thromb Haemost 2009;7:1418-1421.
16. Budde U. Diagnosis of von Willebrand disease subtypes: implications for treatment. Haemophilia 2008;14(suppl 5):27-38.
17. Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemo-philia 2008;14:171-232. (Pubitemid 351343618)
18. Federici AB, Mannucci PM, Castaman G, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2009; 113:526-534.
19. Podda GM, Bucciarelli P, Lussana F, Lecchi A, Cattaneo M. Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time. J Thromb Haemost 2007;5:2393-2398. (Pubitemid 350154348)
20. Favaloro EJ. Laboratory monitoring of therapy in von Willebrand disease: efficacy of the PFA-100 and von Willebrand factor:collagen-binding ac-tivity as coupled strategies. Semin Thromb Hemost 2006;32:566-576. (Pubitemid 44453018)
21. Castaman G, Tosetto A, Goodeve A, et al. The impact of bleeding history, von Willebrand factor and PFA-100 on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD. Br J Haematol 2010;151:245-251.
22. Budde U, Pieconka A, Will K, Schneppenheim R. Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification. Semin Thromb Hemost 2006;32:514-521. (Pubitemid 44157390)
23. ISTH-VWF-SSC. Minutes of the von Willebrand factor subcommittee 2004. Available at: www.isth.org/default/index.cfm/publication/ssc-min-utes. Accessed January 10, 2011.
24. Ruggeri ZM, Zimmerman TS. von Willebrand factor and von Willebrand disease. Blood 1987;70:895-904. (Pubitemid 18022359)
25. Franchini M, Montagnana M, Lippi G. Clinical, laboratory and therapeutic aspects of platelet-type von Willebrand disease. Int J Lab Hematol 2008; 30:91-94. (Pubitemid 351365258)
26. Caron C, Mazurier C, Goudemand J. Large experience with a factor VIII binding assay of plasma von Willebrand factor using commercial reagents. Br J Haematol 2002;117:716-718. (Pubitemid 34539253)
27. Zhukov O, Popov J, Ramos R, et al. Measurement of von Willebrand factor-FVIII binding activity in patients with suspected von Willebrand disease type 2N: application of an ELISA-based assay in a reference laboratory. Haemophilia 2009;15:788-796.
28. Mazurier C, Hilbert L. Type 2N von Willebrand disease. Curr Hematol Rep 2005;4:350-358.
29. Favaloro EJ. Von Willebrand factor collagen-binding (activity) assay in the diagnosis of von Willebrand disease: a 15-year journey. Semin Thromb Hemost 2002;28:191-202. (Pubitemid 34439209)
30. Titani K, Kumar S, Takio K, et al. Amino acid sequence of human von Willebrand factor. Biochemistry 1986;25:3171-3184. (Pubitemid 16056960)
31. Mancuso DJ, Tuley EA, Westfield LA, et al. Structure of the gene for human von Willebrand factor. J Biol Chem 1989;264:19514-19527. (Pubitemid 20008053)
32. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998;67:395-424. (Pubitemid 28411134)
33. Soteh MH, Peake IR, Marsden L, et al. Mutational analysis of the von Willebrand factor gene in type 1 von Willebrand disease using conforma-tion sensitive gel electrophoresis: a comparison of fluorescent and manual techniques. Haematologica 2007;92:550-553. (Pubitemid 350144301)
34. James PD, Notley C, Hegadorn C, et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007;109:145-154. (Pubitemid 46053055)
35. Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand disease (MCMDM-1VWD). Blood 2007;109:112-121. (Pubitemid 46053051)
36. Cumming A, Grundy P, Keeney S, et al. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006;96:630-641. (Pubitemid 44782544)
37. Vidal F, Julia A, Altisent C, Puig L, Gallardo D. Von Willebrand gene tracking by single-tube automated fluorescent analysis of four short tandem repeat polymorphisms. Thromb Haemost 2005;93:976-981. (Pubitemid 40691557)
38. Mayadas TN, Wagner DD. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. Proc Natl Acad Sci USA 1992;89:3531-3535.
39. Haberichter SL, Castaman G, Budde U, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood 2008;111:4979-4985.
40. Haberichter SL, Balistreri M, Christopherson P, et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006;108:3344-3351.
41. Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001;276: 41059-41063.
42. Feys HB, Anderson PJ, Vanhoorelbeke K, Majerus EM, Sadler JE. Multi-step binding of ADAMTS-13 to von Willebrand factor. J Thromb Haemost 2009;7:2088-2095.
43. Sutherland MS, Cumming AM, Bowman M, et al. A novel deletion mutation is recurrent in von Willebrand disease types 1 and 3. Blood 2009;114:1091-1098.
44. Millar CM, Riddell AF, Brown SA, et al. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations. Thromb Hae¬most 2008;99:916-924. (Pubitemid 351705309)
45. Mannucci PM, Lombardi R, Castaman G, et al. von Willebrand disease "Vicenza" with larger-than-normal (supranormal) von Willebrand factor multimers. Blood 1988;71:65-70. (Pubitemid 18050392)
46. Goodeve AC. Vicenza deciphered: modelling the von Willebrand disease enigma Commentary on Accelerated clearance alone explains ultralarge multimers in VWD Vicenza. J Thromb Haemost 2010;8:1271-1272.
47. Schneppenheim R, Federici AB, Budde U, et al. Von Willebrand Disease type 2M "Vicenza" in Italian and German patients: identification of the first candidate mutation (G3864A; R1205H) in 8 families. Thromb Haemost 2000;83:136-140. (Pubitemid 30045489)
48. Eikenboom J, Hilbert L, Ribba AS, et al. Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. J Thromb Haemost 2009;7:1304-1312.
49. Schneppenheim R, Michiels JJ, Obser T, et al. A cluster of mutations in the D3 domain of von Willebrand factor correlates with a distinct subgroup of von Willebrand disease: type 2A/IIE. Blood 2010;115:4894-4901.
50. Hassenpflug WA, Budde U, Obser T, et al. Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis. Blood 2006;107:2339-2345. (Pubitemid 43345553)
51. Casonato A, Sartorello F, Pontara E, et al. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis. Thromb Haemost 2007;98: 1182-1187. (Pubitemid 350239088)
52. Favaloro EJ. von Willebrand disease, type 2B: a diagnosis more elusive than previously thought. Thromb Haemost 2008; 99:630-631; author reply 32-33. (Pubitemid 351549302)
53. James PD, Notley C, Hegadorn C, et al. Challenges in defining type 2M von Willebrand disease: results from a Canadian cohort study. J Thromb Haemost 2007;5:1914-1922. (Pubitemid 47288950)
54. Riddell AF, Gomez K, Millar CM, et al. Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor. Blood 2009;114:3489-3496.
55. Ribba AS, Loisel I, Lavergne JM, et al. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost 2001;86:848-854. (Pubitemid 32834196)
56. Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev 2010;24:123-134.
57. Allen S, Goodeve AC, Peake IR, Daly ME. Endoplasmic reticulum reten¬tion and prolonged association of a von Willebrand's disease-causing von Willebrand factor variant with ERp57 and calnexin. Biochem Biophys Res Commun 2001;280:448-453. (Pubitemid 32912810)
58. VWFdb. International Society on Thrombosis and Haemostasis Scientific and Standardization Committee VWF Information Homepage. Available at: www.vwf.group.shef.ac.uk. Accessed January 10, 2011.
59. Acquila M, Bottini F, DI Duca M, Vijzelaar R, Molinari AC, Bicocchi MP. Multiplex ligation-dependent probe amplification to detect a large deletion within the von Willebrand gene. Haemophilia 2009;15:1346-1348.
60. Hampshire DJ, Bloomer LD, Al-Baba S, et al. Validation of multiplex ligation-dependent probe amplification (MLPA) to detect large-scale dele-tions within the von Willebrand factor (VWF) gene. Platelets 2009; 20(suppl 1):13-14.
61. Keeney S, Bowen D, Cumming A, et al. The molecular analysis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organisation Haemophilia Genetics Laboratory Network. Haemophilia 2008;14:1099-1111.
62. Favaloro EJ. Genetic testing for von Willebrand disease: the case against. J Thromb Haemost 2009;8:6-12.
63. O'Brien LA, James PD, Othman M, et al. Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease. Blood 2003;102: 549-557. (Pubitemid 36841974)
64. Berber E, James PD, Hough C, Lillicrap D. An assessment of the patho-genic significance of the R924Q von Willebrand factor substitution. J Thromb Haemost 2009;7:1672-1679.
65. Hickson N, Hampshire D, Winship P, et al. von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels. J Thromb Haemost 2010;8:1986-1993.
66. Meyer D, Fressinaud E, Gaucher C, et al. Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. INSERM Network on Molecular Abnormalities in von Willebrand disease. Thromb Haemost 1997;78:451-456. (Pubitemid 27289283)
67. Mazurier C, Goudemand J, Hilbert L, et al. Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Pract Res Clin Haematol 2001;14:337-347. (Pubitemid 32677083)
68. James AH, Ragni MV, Picozzi VJ. Bleeding disorders in premenopausal women: (another) public health crisis for hematology? Hematol Am Soc Hematol Educ Program 2006:474-485.
69. Kadir RA, Chi C. Women and von Willebrand disease: controversies in diagnosis and management. Semin Thromb Hemost 2006;32:605-615. (Pubitemid 44453021)
70. Nurden P, Gobbi G, Nurden A, et al. Abnormal VWF modifies megakaryo-cytopoiesis: studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B. Blood 2010;115:2649-2656.
71. Casonato A, Pontara E, Sartorello F, et al. Identifying carriers of type 2N von Willebrand disease: procedures and significance. Clin Appl Thromb Hemost 2007;13:194-200. (Pubitemid 46548371)
72. Goodeve AC, Al-Baba S, Panayi M. Mutations leading to reduced von Willebrand factor binding to factor VIII are uncommon among patients referred for type 2N von Willebrand disease genetic analysis. Platelets 2009;20(S1):S14 O16.
73. Goodeve A. Molecular genetic testing of hemophilia A. Semin Thromb Hemost 2008;34:491-501.
74. Keeney S, Mitchell M, Goodeve A. The molecular analysis of haemophilia A: a guideline from the UK haemophilia centre doctors' organization haemophilia genetics laboratory network. Haemophilia 2005;11:387-397. (Pubitemid 41030841)
75. Zimmermann MA, Oldenburg J, Muller CR, Rost S. Characterization of duplication breakpoints in the factor VIII gene. J Thromb Haemost 2010; 8:2696-2704.
76. Pavlova A, Brondke H, Musebeck J, et al. Molecular mechanisms under-lying hemophilia A phenotype in seven females. J Thromb Haemost 2009;7:976-982.
77. Favaloro EJ, Patterson D, Denholm A, et al. Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis. Br J Haematol 2007;139: 623-626. (Pubitemid 350043816)
78. Giannini S, Cecchetti L, Mezzasoma AM, Gresele P. Diagnosis of platelet-type von Willebrand disease by flow cytometry. Haematologica 2010;95: 1021-1024.
79. Othman M, Favaloro EJ. Genetics of type 2B von Willebrand disease: "true 2B," "tricky 2B," or "not 2B." What are the modifiers of the phenotype? Semin Thromb Hemost 2008;34:520-531.
80. PT-VWD-Registry. Registry on platelet type von Willebrand disease. Available at: http://www.pt-vwd.org/. Accessed January 10, 2011.
81. HGVS. Nomenclature for the description of sequence variations homepage. Available at: http://www.hgvs.org/mutnomen/. Accessed January 10, 2011.
82. Enayat MS, Guilliatt AM, Lester W, et al. Distinguishing between type 2B and pseudo-von Willebrand disease and its clinical importance. Br J Haematol 2006;133:664-666. (Pubitemid 43742784)
83. Sucker C, Michiels JJ, Zotz RB. Causes, etiology and diagnosis of acquired von Willebrand disease: a prospective diagnostic workup to establish the most effective therapeutic strategies. Acta Haematol 2009;121:177-182.
84. Nichols WL, Rick ME, Ortel TL, et al. Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines. Am J Hematol 2009;84:366-370.
85. Federici AB. Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders. Semin Hematol 2006;43:S48-S58. (Pubitemid 43150500)
86. Biss TT, Blanchette VS, Clark DS, et al. Quantitation of bleeding symp¬toms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire. J Thromb Haemost 2010;8:950-956.
87. Demers C, Derzko C, David M, Douglas J. Gynaecological and obstetric management of women with inherited bleeding disorders. J Obstet Gynae-col Can 2005;27:707-732.
88. Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood 2008; 111:3531-3539.
89. Federici AB. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007). Haemophilia 2008;14(suppl 1):5-14.
90. Federici AB. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO.WILL Study. Haemo-philia 2007;13(suppl 5):15-24. (Pubitemid 350253400)
91. Greaves M, Watson HG. Approach to the diagnosis and management of mild bleeding disorders. J Thromb Haemost 2007;5(suppl 1):167-174. (Pubitemid 46958830)
92. ACOG Committee Opinion no. 451: Von Willebrand disease in women. Obstet Gynecol 2009;114:1439-1443.
93. Davis A, Godwin A, Lippman J, Olson W, Kafrissen M. Triphasic norg-estimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Ob-stet Gynecol 2000;96:913-920.
94. Rubin G, Wortman M, Kouides PA. Endometrial ablation for von Wille-brand disease-related menorrhagia\experience with seven cases. Haemo-philia 2004;10:477-482. (Pubitemid 39317757)
95. James AH, Kouides PA, Abdul-Kadir R, et al. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol 2009;201:12 e1-e8.
96. Castaman G, Tosetto A, Rodeghiero F. Pregnancy and delivery in women with von Willebrand's disease and different von Willebrand factor muta-tions. Haematologica 2010;95:963-969.
97. Varughese J, Cohen AJ. Experience with epidural anaesthesia in pregnant women with von Willebrand disease. Haemophilia 2007;13:730-733. (Pubitemid 350018263)
98. Berntorp E. Prophylaxis in von Willebrand disease. Haemophilia 2008; 14(suppl 5):47-53.
99. Berntorp E, Windyga J. Treatment and prevention of acute bleedings in von Willebrand disease\efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate. Haemophilia 2009;15:122-130.
100. Goodeve A, Castaman G, Rodeghiero F, et al. Rate of de novo VWF mutations in patients historically diagnosed with type 1 VWD in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). J Thromb Haemost 2007;5(s2):P-T-189.
101. Castaman G, Rodeghiero F, Tosetto A, et al. Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2006;4:2164-2169. (Pubitemid 44400291)
102. Laurie AD, Hill AM, Harraway JR, et al. Preimplantation genetic diagnosis for hemophilia A using indirect linkage analysis and direct genotyping approaches. J Thromb Haemost 2010;8:783-789.
103. El-Toukhy T, Bickerstaff H, Meller S. Preimplantation genetic diagnosis for haematologic conditions. Curr Opin Pediatr 2010;22:28-34.
104. Schneppenheim R, Budde U, Beutel K, et al. Response to DDAVP in children with von Willebrand disease type 2. Hamostaseologie 2009;29: 143-148.
105. Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000;84:160-174. (Pubitemid 30601459)
106. Mannucci PM, Federici AB. Antibodies to von Willebrand factor in von Willebrand disease. Adv Exp Med Biol 1995;386:87-92.
107. Jenkins PV, O'Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 2006; 46:1836-1844. (Pubitemid 44435738)
108. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987;69:1691-1695. (Pubitemid 17091627)
109. Davies JA, Collins PW, Hathaway LS, Bowen DJ. Effect of von Wille-brand factor Y/C1584 on in vivo protein level and function and interaction with ABO blood group. Blood 2007;109:2840-2846. (Pubitemid 46482079)
110. Mazurier C, Rodeghiero F. Recommended abbreviations for von Wille-brand factor and its activities. Thromb Haemost 2001;86:712. (Pubitemid 32743290)